Pharming Group (NASDAQ:PHAR) Shares Gap Up – What’s Next?

Pharming Group (NASDAQ:PHAR) gapped up before the market opened on Tuesday . The stock had previously closed at $8.91, but opened at $9.14. Pharming Group shares last traded at $9.25, with a volume of 752 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and issued a $37.00 price objective on shares of Pharming Group in a report on Thursday, October 10th.

Pharming Group Stock Up 0.3 %

The stock’s 50 day simple moving average is $7.97 and its two-hundred day simple moving average is $8.58. The firm has a market cap of $602.06 million, a P/E ratio of -57.88 and a beta of 0.15. The company has a debt-to-equity ratio of 0.40, a current ratio of 3.39 and a quick ratio of 2.65.

Pharming Group (NASDAQ:PHAR) last issued its earnings results on Thursday, August 1st. The company reported ($0.01) earnings per share (EPS) for the quarter. The firm had revenue of $74.09 million during the quarter, compared to analysts’ expectations of $71.95 million. Pharming Group had a negative return on equity of 5.69% and a negative net margin of 4.65%. During the same period last year, the firm posted $0.02 earnings per share. As a group, research analysts forecast that Pharming Group will post -0.15 earnings per share for the current year.

Institutional Investors Weigh In On Pharming Group

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC increased its stake in shares of Pharming Group (NASDAQ:PHAR) by 32.3% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 23,435 shares of the company’s stock after purchasing an additional 5,725 shares during the period. Silverberg Bernstein Capital Management LLC’s holdings in Pharming Group were worth $196,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 0.03% of the company’s stock.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.